Cited by 41Diabetes Management and ResearchHyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Automated insulin delivery with remote real-time continuous glucose monitoring for hospitalized patients with diabetes: a multicenter, single-arm, feasibility trial

Open access
Davis, Georgia M., Hughes, Michael S., Brown, Sue A., Sibayan, Judy, Perez-Guzman, M. Citlalli, Stumpf, Meaghan, Thompson, Zachary, Basina, Marina +12 more·2023·Diabetes Technology & Therapeutics

Abstract

Introduction: Multiple daily injection insulin therapy frequently fails to meet hospital glycemic goals and is prone to hypoglycemia. Automated insulin delivery (AID) with remote glucose monitoring offers a solution to these shortcomings. Research Design and Methods: In a single-arm multicenter pilot trial, we tested the feasibility, safety, and effectiveness of the Omnipod 5 AID System with real-time continuous glucose monitoring (CGM) for up to 10 days in hospitalized patients with insulin-requiring diabetes on nonintensive care unit medical–surgical units. Primary endpoints included the proportion of time in automated mode and percent time-in-range (TIR 70–180 mg/dL) among participants with >48 h of CGM data. Safety endpoints included incidence of severe hypoglycemia and diabetes-related ketoacidosis (DKA). Additional glycemic endpoints, CGM accuracy, and patient satisfaction were also explored. Results: Twenty-two participants were enrolled; 18 used the system for a total of 96 days (mean 5.3 ± 3.1 days per patient), and 16 had sufficient CGM data required for analysis. Median percent time in automated mode was 95% (interquartile range 92%–98%) for the 18 system users, and the 16 participants with >48 h of CGM data achieved an overall TIR of 68% ± 16%, with 0.17% ± 0.3% time <70 mg/dL and 0.06% ± 0.2% time <54 mg/dL. Sensor mean glucose was 167 ± 21 mg/dL. There were no DKA or severe hypoglycemic events. All participants reported satisfaction with the system at study end. Conclusions: The use of AID with a disposable tubeless patch-pump along with remote real-time CGM is feasible in the hospital setting. These results warrant further investigation in randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2023.0304

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Data on inpatient use of hybrid closed-loop systems (currently commercially available automated insulin delivery [AID] devices) are limited to feasibility trials.

    “Data on inpatient use of hybrid closed-loop systems (currently commercially available automated insulin delivery [AID] devices) are limited to feasibility trials (58).”

    From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [58]

    The Introduction and Statistical Analysis sections identify this inpatient Omnipod 5 study as a single-arm feasibility trial. They do not establish that data on all commercially available hybrid closed-loop systems are limited to feasibility trials; the Introduction also describes comparative inpatient studies of a different closed-loop system. Page numbers are unavailable in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Davis, G. M., Hughes, M. S., Brown, S. A., Sibayan, J., Perez-Guzman, M. C., Stumpf, M., Thompson, Z., Basina, M., Patel, R. M., Hester, J., Abraham, A., Ly, T. T., Chaney, C., Tan, M., Hsu, L., Kollman, C., Beck, R. W., Lal, R., Buckingham, B., & Pasquel, F. J.
Affiliations
  • Emory University (US)
  • Stanford Medicine (US)
  • University of Virginia (US)
  • Jaeb Center for Health Research (US)
  • Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Insulet (United States) (US)
Corresponding author
Pasquel, Francisco J.
Venue
Diabetes Technology & Therapeutics
Published
2023-10
Volume
25
Issue
10
Pages
677-688
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W4385798381
Cited by
41
References
27
Citations by year
2026: 14 · 2025: 13 · 2024: 13 · 2023: 1
FWCI
8.41
Type
journal article
Language
en
Open access
Locations
  • Diabetes Technology & Therapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Insulet Corporation
  • National Institutes of Health
  • National Institute of General Medical Sciences (K23GM128221)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K12DK122550, K23DK122199, K23DK122017, P30DK116074, T32DK007217, P30DK111024)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
artificial pancreas, continuous glucose monitoring, Omnipod 5, time in range, hypoglycemia, diabetic ketoacidosis, medical-surgical units, feasibility, patient satisfaction, CGM accuracy
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Feasibility Studies, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Pilot Projects, Blood Glucose Self-Monitoring, Diabetic Ketoacidosis, Insulin, Regular, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review